Cell Therapy Products in Alzheimer Disease.
- Author:
Hyeon Jin SONG
1
;
Tae Hee KIM
;
Hae Hyeog LEE
;
Jun Mo KIM
;
Yoo Jin PARK
;
Arum LEE
;
Soo Ah KIM
;
Hye Ji CHOI
Author Information
- Publication Type:Review
- Keywords: Alzheimer's disease; Cell- and tissue-based therapy; Menopause; Stem cells
- MeSH: Aged; Aging; Alzheimer Disease*; Amyloid; Brain; Cell- and Tissue-Based Therapy*; Dementia; Estrogens; Female; Fetal Blood; Humans; Menopause; Mesenchymal Stromal Cells; Public Health; Stem Cells
- From:Journal of Menopausal Medicine 2017;23(1):1-4
- CountryRepublic of Korea
- Language:English
- Abstract: We are rapidly becoming an aging society, with the ongoing increase in challenges of the elderly. The age-related cognitive decline in accordance with aging society is of major importance in public health. Recent studies have proved the impacts of sex-steroid hormone on the brain; compliant with aging, menopause and decrease in estrogen have an effect on the occurrence and prevention of Alzheimer's disease. A new hypothesis states that Alzheimer's disease is a postmenopausal dementia, and is a negative form of estrogen deficiency. In this review article, we reckoned the cause of postmenopausal Alzheimer's disease. We further investigated new cell therapies for postmenopausal Alzheimer's disease, which are under development in some pharmaceutical companies. One remedy is cell therapy that inhibits the amyloid beta formation, and the other is the umbilical cord blood derived mesenchymal stem cell therapy.
